We recently compiled a list of the These 10 Firms Dominated Last Week’s Rally. In this article, we are going to take a look ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

We recently published a list of These 10 Firms Took A Hit on Friday. In this article, we are going to take a look at where ...

Shares of ImmunityBio (NASDAQ:IBRX) were up 15% in midday trading Thursday, the day after it issued updates on its regulatory ...

D. Boral Capital reiterated their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. D. Boral Capital ...

CULVER CITY, Calif., January 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced the completion of the submissions of its marketing authorization applications (MAA) for ANKTIVA ...

ImmunityBio also said it will submit a regulatory filing for an alternative source of Bacillus Calmette-Guerin, a drug which treats bladder cancer. The company expects to produce large quantities of ...

ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...

ImmunityBio, Inc. (NASDAQ:IBRX – Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low ...

ImmunityBio is at the forefront of developing innovative immunotherapies and cell therapies. The company has a vertically integrated approach, allowing it to oversee every step of development, from ...

BTIG analyst Justin Zelin initiated coverage of ImmunityBio (IBRX) with a Buy rating and $6 price target Lead product Anktiva is approved in ...